[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Primorsky Regional General Hospital #1\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100627660","comparative-analysis-of-analgesic-approaches-in-the-early-period-after-cabg-100627660",false,"NCT07451522","Comparative Analysis of Analgesic Approaches in the Early Period After CABG","Comparative Characteristics of Analgesia Methods in the Early Postoperative Period After Coronary Artery Bypass Grafting (CABG)","CABG-PAIN","Inclusion Criteria:\n\n* ASA score less then 3, Signed inform consent, Absence of preoperative drugs administration that affects patient's perception of pain, No active infection process, BMI index \\>18,5 kg\\\\m2 and \\\u003C 35 kg\u002Fm2, CABG, Age 18-75 years\n\nExclusion Criteria (the presence of at least one is sufficient):\n\n* Failure to meet the inclusion criteria.\n* High severity according to ASA (class IV or higher), which is associated with a high probability of prolonged mechanical ventilation, hemodynamic instability, and inability to use drugs affecting cardiac output and\u002For total peripheral vascular resistance.\n* Contraindications to the use of tafalgin and\u002For morphine in accordance with the approved Summary of Product Characteristics (hypersensitivity to tafalgin, morphine, other opioids, or any excipients).\n* Pregnancy or lactation.\n* Acute or prolonged chronic intoxication with drugs or substances depressing the central nervous system (alcohol, barbiturates, opioid drugs, benzodiazepines).\n* Use of monoamine oxidase inhibitors (MAOIs) or less than 14 days since their discontinuation.\n* Liver cirrhosis, Child-Pugh class C.\n* Acute renal failure requiring renal replacement therapy.\n* Unresected malignant neoplasm.\n* Mesenteric thrombosis or another severe abdominal pain syndrome of unclear etiology at the time of inclusion.\n* Simultaneous participation in another clinical study.\n* Marked CNS depression due to any cause, except for acute poisoning.\n* COPD stage III and\u002For bronchial asthma in the exacerbation phase.\n* Any clinically significant condition, disease, or circumstance in the medical history that, in the opinion of the investigator, precludes participation in the study.\n* Psychiatric, physical, or other conditions preventing adequate assessment of the patient's behavior or proper compliance with the study protocol.\n* Postoperative hemodynamic instability requiring high-dose inotropic and\u002For vasopressor support (epinephrine \\> 0.1 μg\u002Fkg\u002Fmin, dopamine \\> 10 μg\u002Fkg\u002Fmin, norepinephrine \\> 0.2 μg\u002Fkg\u002Fmin) and\u002For mechanical circulatory support.\n* Refusal to participate in the study.","ALL","18 Years","75 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to study postoperative analgesia in patients undergoing CABG. And learn if tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) treats pain not inferiory then morphine. The main questions it aims to answer are:\n\nDoes tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) lower the VAS score same way as a morphine? What medical problems do participants have when taking tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid)?\n\nParticipants will:\n\nGroup (1)- subcutaneous single dose of morphine 10 mg would be administred based on VAS score \\> 3 during 24 hours after CABG.\n\nExprimental group (2)- subcutaneous single dose of tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) - 0.4 mg would be administred based on VAS score \\> 3 during 24 hours after CABG.\n\nEfficacy was assessed using the VAS scale decreassion. Hemodynamic parameters and arterial blood gases were also assessed.",[28,29,30],"CAD - Coronary Artery Disease","CABG","Analgesia Assessment",[29,32,33,34,35],"CAD","Morphine","Tafalgin","VAS","RECRUITING","2026-02-28",{"date":39,"type":40},"2026-03-05","ACTUAL",{"date":42,"type":40},"2025-12-01",{"date":44,"type":22},"2026-03-15",{"name":46,"class":47},"Primorsky Regional General Hospital #1","OTHER_GOV",""]